Invention Application
- Patent Title: Afucosylated Anti-FGFR2IIIB Antibodies
-
Application No.: US17554423Application Date: 2021-12-17
-
Publication No.: US20220168416A1Publication Date: 2022-06-02
- Inventor: Thomas Harding , Kristen Pierce , Namrata Patil , Thomas Brennan , Julie Hambleton
- Applicant: Five Prime Therapeutics, Inc.
- Applicant Address: US CA Thousand Oaks
- Assignee: Five Prime Therapeutics, Inc.
- Current Assignee: Five Prime Therapeutics, Inc.
- Current Assignee Address: US CA Thousand Oaks
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K33/243 ; A61K31/337 ; A61K31/513 ; A61K45/06
Abstract:
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Information query
